EUCTR2017-000504-20-IT进行中（未招募）1 期
A phase II trial of vemurafenib plus cobimetinib in patients treated with prior first-line systemic immunotherapy for inoperable locally advanced or metastatic melanoma - VECODUE
FONDAZIONE MELANOMA ONLUS0 个研究点目标入组 62 人开始时间: 2021年5月24日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 62
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1)Patients must have histologically confirmed, unresectable stage IIIc or stage IV metastatic melanoma, as defined by the American Joint Committee on Cancer 7th edition. Unresectability of stage IIIc disease must have confirmation from a surgical oncologist
- •2)Patients with advanced melanoma who have received one prior immunotherapy systemic regimen for advanced disease, for whom vemurafenib/cobimetinib treatment has been scheduled by the treating physician.
- •3)Adjuvant treatment is allowed, except for anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 agents
- •4)Patients must be naïve to treatment for locally advanced unresectable or metastatic with BRAF/MEK inhibitors
- •5)Documentation of BRAFV600 mutation-positive status in melanoma tumor tissue BRAF V600 mutation test
- •6)At least one measurable lesion according to disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria
- •7)Eastern Cooperative Oncology Group (ECOG) Performance Status of 0- 2
- •8)Male or female patient aged = 18 years
- •9)Able to participate and willing to give written informed consent prior to performance of any study-related procedures and to comply with the study protocol
- •10)Life expectancy = 12 weeks
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 31
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 31
排除标准
- •1)History of any prior systemic treatment for unresectable stage IIIc or stage IV melanoma (prior anti RAF or MEK agents) other than one prior first-line immunotherapy
- •2)Palliative radiotherapy within 14 days prior to the first dose of study treatment
- •3)Major surgery or traumatic injury within 14 days prior to first dose of study treatment
- •4)Patients with active malignancy (other than BRAF- mutated melanoma) or a previous malignancy within the past 3 years are excluded; except for patients with resected melanoma, resected BCC, resected cutaneous SCC, resected melanoma in-situ, resected carcinoma in-situ of the cervix, and resected carcinoma in-situ of the breast
- •Exclusion Criteria Based on Organ Function
- •5)History of, or evidence of retinal pathology on ophthalmologic examination that is considered a risk factor for neurosensory retinal detachment/central serouschorioretinopathy (CSCR), retinal vein occlusion (RVO) or neovascularmacular degeneration
- •6)The risk factors for RVO are listed below. Patients will be excluded if they currently have the following conditions:
- •a.Uncontrolled glaucoma with intra-ocular pressures =21 mmHg.
- •b.Serum cholesterol =Grade 2
- •c.Hypertriglyceridemia = Grade 2
- •d.Hyperglycemia (fasting) =Grade 2
- •7)History of clinically significant cardiac dysfunction, including the following:
- •a.Current unstable angina
- •b.Symptomatic congestive heart failure of New York Heart Association class 2 or higher
- •c.History of congenital long QT syndrome or mean (average of triplicate measurements) QTcF = 450 msec at baseline or uncorrectable abnormalities inserum electrolytes (sodium, potassium, calcium, magnesium, phosphorus)
- •d.Uncontrolled hypertension= Grade 2 (patients with a history hypertension controlled with anti-hypertensives to = Grade 1 are eligible).
- •e.Left ventricular ejection fraction (LVEF) below institutional lower limit of normal (LLN) or below 50%, whichever is lower
- •Central Nervous System:
- •8)Patients with active/symptomatic CNS lesions are excluded
研究者
相似试验
进行中（未招募）
1 期
Clinical Trial to evaluate the efficacy of vemurafenib in combination with cobimetinib (continuous and intermittent) in BRAFV600-mutation positive patients with unresectable locally advanced or metastatic melanoma.BRAFV600-mutation positive patients with unresectable locally advanced or metastatic melanoma.MedDRA version: 17.1 Level: LLT Classification code 10053571 Term: Melanoma System Organ Class: 100000004864EUCTR2014-005277-36-ESGrupo Español Multidisciplicinar de Melanoma (GEM)116
终止
2 期
Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain MetastasesActive Melanoma Brain MetastasesNCT02230306Melissa Burgess, MD5
进行中（未招募）
1 期
Vemurafenib and Cobimetinib combination in BRAF mutated melanoma with brain metastasisPatients with brain metastasis (BM) from BRAFV600-mutated cutaneous melanoma. Patients will be enrolled into three cohorts: A. Neurologically asymptomatic patients who have not received prior local treatment (cohort A)B. Neurologically asymptomatic patients who have received prior local treatment (cohort B)C. Neurologically symptomatic patients who have or have not received prior local treatment (cohort C).MedDRA version: 18.0 Level: LLT Classification code 10027481 Term: Metastatic melanoma System Organ Class: 100000004864EUCTR2014-001671-30-FRCentre Eugène Marquis137
进行中（未招募）
1 期
Evaluate the safety and the efficacy of Vemurafenib/PEG-interferon in melanoma patientsEvaluate the safety and the efficacy of Vemurafenib/PEG-interferon combination and the IFNAR1 upregulation lead by this treatment in advanced melanoma patients harboring the V600BRAF mutationMedDRA version: 14.1Level: LLTClassification code 10053571Term: MelanomaSystem Organ Class: 100000004864EUCTR2013-003730-33-ITFondazione Melanoma ONLUS48
已完成
3 期
A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic MelanomaMalignant MelanomaNCT01689519Hoffmann-La Roche495